Skip to main content

Table 1 Baseline characteristics of the study participants

From: Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial

Characteristic

Patch-based monitoring (ACTIVE)

(n = 43)

Short-duration Holter (CONTROL)

(n = 47)

P value

Age, year

70.7 ± 12.6

70.0 ± 13.9

0.82

Sex, no. (%)

 Male

26 (60.5)

29 (61.7)

1.00

 Female

17 (39.5)

18 (38.3)

 

Race or ethnic group, no. (%)

 Asian

1 (2.3)

2 (4.3)

0.80

 Black

11 (25.6)

10 (21.3)

 

 White

31 (72.1)

35 (74.5)

 

Recruitment site, no. (%)

 King’s College Hospital

12 (27.9)

22 (46.8)

0.08

 Princess Royal University Hospital

31 (72.1)

25 (53.2)

 

Index event, no. (%)

 Stroke

35 (81.4)

43 (91.5)

0.22

 TIA

8 (18.6)

4 (8.5)

 

Prior stroke or TIA, no. (%)

12 (27.9)

7 (14.9)

0.20

Score on NIH stroke scale (stroke patients)a

2.3 ± 3.7

2.1 ± 2.6

0.90

Score on ABCD2 (TIA patients), no.

4.1 ± 0.6

4.2 ± 0.8

0.87

Hypertension, no. (%)

26 (60.5)

30 (63.8)

0.83

Diabetes, no. (%)

10 (23.3)

10 (21.3)

1.00

CHADS2VASc2 score, no.b

4.4 ± 1.2

4.3 ± 1.0

0.61

Ischaemic heart disease, no. (%)

8 (18.6)

5 (10.6)

0.37

Hypercholesterolaemia, no. (%)

17 (39.5)

17 (36.2)

0.83

Smoking status, no. (%)

 Ex-smoker

12 (27.9)

5 (10.6)

0.27

 Current smoker

6 (14)

10 (21.3)

 

Use of antiplatelet, no. (%)c

 None

30 (69.8)

33 (70.2)

0.26

 Aspirin

5 (11.6)

10 (21.3)

 

 Clopidogrel

6 (14.0)

4 (8.5)

 

 Aspirin and Clopidogrel

2 (4.7)

0 (0)

 

No. of days from index event to randomisation

2.0 ± 1.2

1.9 ± 1.1

0.60

  1. Plus–minus values are mean ± SD. P values were calculated with the use of Student’s t test, Wilcoxon Mann–Whitney Rank-Sum test or Fisher’s exact test, as appropriate. TIA denotes transient ischaemic attack
  2. NIH National Institutes of Health, TIA transient ischaemic attack
  3. aScores on the National Institutes of Health Stroke Scale range from 0 to 42, with higher scores indicating more severe neurologic deficits. The score was not reported for three patients in the patch-based monitoring (ACTIVE) group and four patients in the 24-h Holter monitoring group
  4. bScores on the CHADS2VASc2 risk assessment range from 0 to 6, with higher scores indicating a greater risk of stroke
  5. cAntiplatelet therapy before the index stroke or TIA